Entera Bio Raises $275 Million in Private Placement to Advance Oral PTH Therapy EB613 Toward NDA Filing

The Quick Take

• Entera Bio raised $275 million in a private placement to fund advancement of EB613, its oral parathyroid hormone therapy for osteoporosis
• EB613 targets the large osteoporosis treatment market where existing injectable PTH therapies (teriparatide, abaloparatide) face patient compliance barriers
• The capital raise positions Entera to fund pivotal trials and a potential New Drug Application filing with the FDA

Entera Bio, a clinical-stage biopharmaceutical company focused on oral delivery of large peptide molecules, raised $275 million in a private placement to accelerate the development of EB613, its oral parathyroid hormone (PTH) analog targeting moderate-to-severe osteoporosis. The raise is significant given that oral delivery of peptide hormones — historically limited by poor bioavailability in the gastrointestinal tract — represents a formulation challenge that Entera's technology platform claims to have solved. If EB613 demonstrates comparable efficacy to injectable teriparatide (Forteo) in pivotal clinical trials, the oral administration route would provide a major patient convenience advantage in the multi-billion dollar osteoporosis therapeutic market.

The $275 million private placement reflects strong biotech investor appetite for differentiated osteoporosis platform bets. Current standard-of-care bone-building injectable therapies — Eli Lilly's teriparatide and Radius Health's abaloparatide — face real-world compliance limitations because they require daily self-injection; oral PTH would remove that barrier for a large patient population. For Entera's competitive positioning, the capital runway needs to be sufficient to fund at least two pivotal Phase 3 trials required for NDA submission, an undertaking that typically requires $150-300 million. The timing of this raise suggests Entera is entering or preparing to enter pivotal-stage development.

Key signals to monitor include Entera's disclosure of specific Phase 3 trial initiation timelines and patient enrollment start dates, which will provide the clearest indication of when pivotal data could be available. Any interim data readout from ongoing studies will be a critical catalyst. The macro variable: FDA policy on oral peptide delivery remains the key regulatory risk — if the agency requires Entera to meet a higher-than-expected pharmacokinetic/pharmacodynamic threshold for oral PTH equivalence to injectable, the development path lengthens materially.

Synthesized from 1 source.